ArticleFrontiers in cell and developmental biology2026
Concurrent activation of multiple programmed cell death pathways predicts 28-day mortality in pediatric sepsis: a retrospective PICU cohort study with differential sedative agent use between survivors and non-survivors.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically characterize the expression profiles of biomarkers associated with multiple programmed cell death (PCD) pathways-including apoptosis, pyroptosis, necroptosis, and ferroptosis-in pediatric intensive care unit (PICU) patients with sepsis, elucidate their associations with organ dysfunction severity and clinical prognosis, and identify independent predictors of 28-day all-cause mortality in children. Methods: A retrospective cohort study was conducted on 208 pediatric sepsis patients (aged 1 month to 18 years) admitted to the PICU of Jingzhou First People's Hospital between January 2021 and December 2023. Based on 28-day survival outcomes, patients were divided into a survival group (n = 148) and a death group (n = 60). Plasma biomarkers for apoptosis (caspase-3, caspase-9, Bcl-2, Bax), pyroptosis (NLRP3, caspase-1, GSDMD, IL-1β, IL-18), necroptosis (RIPK1, RIPK3, MLKL), ferroptosis (GPX4, ferritin, MDA, 4-HNE), and damage-associated molecular patterns (DAMPs: HMGB1, HSP70, S100A8/A9) were measured within 24 h of PICU admission. ROC analysis, Kaplan-Meier survival analysis, and Cox proportional hazards regression were employed for prognostic evaluation. Results: The 28-day mortality rate was 28.8% (60/208). Non-survivors demonstrated significantly elevated NLRP3, caspase-1, GSDMD, IL-18, RIPK3, MLKL, HMGB1, ferritin, and MDA, and significantly lower GPX4 and Bcl-2/Bax ratio compared to survivors (all P < 0.001). NLRP3 demonstrated the highest individual predictive value (AUC = 0.836), and the combined biomarker panel (NLRP3+GPX4+HMGB1) substantially outperformed pSOFA score alone (AUC = 0.896 vs. 0.786). Multivariate Cox regression identified NLRP3 >2.45 ng/mL (HR = 2.847, 95%CI: 1.682-4.819), GPX4 <12.3 ng/mL (HR = 2.234, 95%CI: 1.458-3.425), HMGB1 >15.6 ng/mL (HR = 1.856, 95%CI: 1.142-3.015), and pSOFA score >8 (HR = 1.672, 95%CI: 1.089-2.567) as independent predictors of 28-day mortality (C-index = 0.821). Conclusion: Multiple PCD pathways are concurrently activated in pediatric sepsis, with NLRP3-driven pyroptosis and GPX4-deficient ferroptosis as the strongest independent mortality predictors. From a pediatric anesthesiology perspective, anesthetic agents with documented anti-pyroptotic or anti-ferroptotic properties-including dexmedetomidine and propofol-may represent adjunctive organ-protective strategies. Combined PCD biomarker profiling provides additive prognostic value beyond conventional severity scores and identifies mechanistically distinct therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.